Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA

OBJECTIVE: Circulating tumor DNA (ctDNA) monitoring proves to be a promising approach to assess response and predict survival in epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKIs). However, whether the dynamic ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Xu, Ziyi, Wang, Shouzheng, Zhu, Yixiang, Ma, Di, Mu, Yuxin, Ying, Jianming, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346168/
https://www.ncbi.nlm.nih.gov/pubmed/35778830
http://dx.doi.org/10.1111/1759-7714.14545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346168/
https://www.ncbi.nlm.nih.gov/pubmed/35778830
http://dx.doi.org/10.1111/1759-7714.14545

Ejemplares similares